CD16 was good to go, but they decided to get more
Post# of 144708
![Avatar](/images/ProfileImages/1227900469_64555_mark.jpg)
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)